The US Food and Drug Administration (FDA) has added a boxed warning to febuxostat after a postmarketing safety clinical trial found an increased risk of cardiovascular-related death and all-cause mortality compared to allopurinol. The FDA said it was also limiting the approved use of febuxostat to second-line treatment in gout after allopurinol. “Health care professionals should ...
Already a member?
Enter your email to keep reading.